INDIA – Indian biotech company Mylab Discovery Solutions has introduced two types of rapid point-of-care (PoC) tests for the detection of dengue infections.

The newly launched PoC tests for the detection of dengue infections include a rapid gold test and a high-accuracy dry luminescence assay test.

The rapid PoC dengue tests will provide clinicians with a highly accurate option for the early diagnosis of dengue infections where access to traditional laboratory facilities is limited.

In a press statement, Hasmukh Rawal, Co-founder and Managing Director of Mylab Discovery Solutions, said: “These rapid point-of-care tests provide healthcare professionals with accurate and efficient tools for timely diagnosis, ultimately aiding in effective disease management.”

These tests will allow clinicians to identify the early stages of dengue infection, differentiate the three distinct phases of the infection, and determine the progression of the infection from onset to recovery.

The tests differentiate between IgM and IgG antibodies. In the case of primary dengue infection, detectable levels of IgM antibodies emerge as early as the third day after infection and generally persist for 2-6 months.

The rapid tests also provide better sensitivity and specificity than traditional tests, delivering accurate and reliable results in less than 20 minutes.

Following IgM, dengue IgG antibodies appear around day seven of the fever during the primary infection and remain present for an extended period, potentially lasting for years.

As a result, Mylab’s rapid point-of-care dengue tests will provide clinicians with a highly accurate option that is less time-consuming in comparison to traditional testing methods.

Additionally, the rapid tests are easy to use, do not require a laboratory setup, are less time-consuming in comparison to traditional testing methods, and can be deployed in resource-limited settings.

Mylab’s rapid point-of-care dengue tests can be used in resource-limited regions to support dengue screening programmes thus enabling prompt and targeted interventions and treatment.

Moreover, the product launches will help Mylab to further expand its presence in the global point-of-care diagnostics market size, which is projected to grow from US$45.85 billion in 2023 to US$78.11 billion by 2030.

It represents the company’s commitment to providing healthcare professionals with advanced tools to facilitate early diagnosis and better patient outcomes.

This news comes shortly after Mylab introduced the Mybox+ diagnostic device with a range of important tests, including a Thyroid panel, Cardiac marker, and biomarker.

Meanwhile, the Indian biotech company is integrating Qure.ai’s AI technology into its upcoming x-ray device for screening tuberculosis.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.